(continued)
Researchers have compiled a detailed molecular profile of an individual, with the goal of learning how to construct an integrative personal "omics" profile, how the profile changes in health and disease, and how to use this information to gauge risk and better understand disease states.
The report, published in Cell, analyzed molecular changes observed in health and disease, including the unexpected development of type 2 diabetes during the study. The group leader Michael Snyder, PhD, chair of the Department of Genetics, Stanford University School of Medicine, provided about 20 blood samples during the 14-month study for analyses, using peripheral blood mononuclear cells, plasma, and sera. Although the 14-month study has now been published, the sampling and analysis continue. "Realistically, other things may happen to me over the rest of my life, and we hope to capture those as well," Initial whole-genome sequencing (WGS) of Dr. Snyder's DNA was performed using several technologies, as was exome sequencing (the part of the genome coding for proteins and other gene products).
Overall, his blood samples were analyzed for nearly 40,000 variables, including profiles of 19,000 or more transcripts that carry the information from about 12,000 genes, levels of 4000 proteins, and 5000 metabolite peaks (only 1000 are known). The results revealed disease variants associated with emphysema, aplastic anemia, type 2 diabetes, and hypertriglyceridemia, among other diseases. The RiskOGram algorithm, which "integrates information from multiple alleles associated with disease risk," indicated an elevated risk for coronary artery disease, basal cell carcinoma, hypertriglyceridemia, and type 2 diabetes.
"Right now we're trying to collect as much information as we can, and we'd like to do this, obviously, with multiple individuals. It may be, at the end of the day, you don't need to make 40,000 measurements like we did on me," said Dr. Snyder. However, "for the average person, I still think it's going to be more than 20 like we do now.... We should be profiling hundreds, if not thousands, kind of routinely as part of an exam." More information is available that way, he said. Asked which analyses were most informative clinically, Dr. Snyder laughed. "I know this will sound like a cop-out, but for me, it was best to analyze everything."
The transcriptome found the most information, but if they had only looked at the transcriptome, they would have missed other equally relevant things, he said. "Some signatures showed up with just the proteomics, and some only showed up with all 3 profiles [transcriptome, proteome, metabolome].... There's really more information in all 3 than in any 1 of these alone," Dr. Snyder added. "We didn't know that for sure going in, but it was refreshing and somewhat reassuring to see this. It makes sense that you'll get a more complete picture when you follow everything."
One goal of the study was to compare molecular analyses in health and disease. Dr. Snyder developed 2 viral infections during the study: a rhinovirus infection on day 0, and a respiratory syncytial virus (RSV) infection starting on day 289. Twelve days later (day 301), his glucose levels became elevated. The elevation lasted several months until, based on glucose levels and HbA1c, his physician diagnosed type 2 diabetes on day 369. "People have associated diabetes with stress responses before, but to the best of my knowledge, not with viral infections. So this was a new angle," Dr. Snyder noted. "It could be that the virus acted like a stress inducer. Our interpretation of this is that my genome has me predisposed and that, in combination with the viral infection, maybe the stress-response part of the viral infection induced the disease." Asked why this infection induced diabetes when previous infections had not, Dr. Snyder said: "This RSV is a pretty nasty one. Another factor may be the case as well: I'm in my 50s and, to be honest, that's when things break down. It's quite likely that the combination of being in my 50s, with this viral stress and, again, my genome combination is what triggered it."
Diabetes should be regarded as "hundreds of diseases," noted Dr. Snyder. "Some people are insulin-resistant, some aren't; some respond to metformin, some don't; some seem to be associated with inflammation, some aren't. So I think diabetes probably is many diseases, all lumped together, because the 1 common characteristic is high glucose. I'm hopeful that by doing more of these sorts of studies, we can look at the molecular breakdown of how many types there are, and then be able to better stratify it and better treat it," Dr. Snyder said.
"I foresee that a longitudinal 'Omics' study as described in Snyder's landmark paper will indeed become common in the next 10 to 20 years," said Jan Korbel, PhD, group leader at the European Molecular Biology Laboratory, Heidelberg, Germany.
"A first promising application would be in families with particular hereditary risk factors, where whole-omics profiling could be used to monitor disease onset closely." George M. Church, PhD, professor of genetics at Harvard Medical School, Boston, Massachusetts, anticipates that work-ups of this type might become common for individuals in "maybe 4 years."
Eric J. Topol, MD, professor of translational genomics at the Scripps Research Institute, La Jolla, California, expects that such work-ups could "be common now for select individuals with a rare, disabling, even life-threatening condition.
Unlike the Snyder study of 20 serial blood draws...a single assessment is eminently doable and could shed considerable light on root cause and potential targeted therapy." "I think it's going to be the future of medicine," concluded Dr. Snyder. "I'd love to see medicine in the future be a case where you get a little prick in your finger, just like a diabetes test, and you measure 5000 things instead of 1 thing (just glucose) right now. I'd love to see it be a home test, where you can monitor your own health routinely," he said. "That's my vision for medicine in the future."
Researchers have compiled a detailed molecular profile of an individual, with the goal of learning how to construct an integrative personal "omics" profile, how the profile changes in health and disease, and how to use this information to gauge risk and better understand disease states.
The report, published in Cell, analyzed molecular changes observed in health and disease, including the unexpected development of type 2 diabetes during the study. The group leader Michael Snyder, PhD, chair of the Department of Genetics, Stanford University School of Medicine, provided about 20 blood samples during the 14-month study for analyses, using peripheral blood mononuclear cells, plasma, and sera. Although the 14-month study has now been published, the sampling and analysis continue. "Realistically, other things may happen to me over the rest of my life, and we hope to capture those as well," Initial whole-genome sequencing (WGS) of Dr. Snyder's DNA was performed using several technologies, as was exome sequencing (the part of the genome coding for proteins and other gene products).
Overall, his blood samples were analyzed for nearly 40,000 variables, including profiles of 19,000 or more transcripts that carry the information from about 12,000 genes, levels of 4000 proteins, and 5000 metabolite peaks (only 1000 are known). The results revealed disease variants associated with emphysema, aplastic anemia, type 2 diabetes, and hypertriglyceridemia, among other diseases. The RiskOGram algorithm, which "integrates information from multiple alleles associated with disease risk," indicated an elevated risk for coronary artery disease, basal cell carcinoma, hypertriglyceridemia, and type 2 diabetes.
"Right now we're trying to collect as much information as we can, and we'd like to do this, obviously, with multiple individuals. It may be, at the end of the day, you don't need to make 40,000 measurements like we did on me," said Dr. Snyder. However, "for the average person, I still think it's going to be more than 20 like we do now.... We should be profiling hundreds, if not thousands, kind of routinely as part of an exam." More information is available that way, he said. Asked which analyses were most informative clinically, Dr. Snyder laughed. "I know this will sound like a cop-out, but for me, it was best to analyze everything."
The transcriptome found the most information, but if they had only looked at the transcriptome, they would have missed other equally relevant things, he said. "Some signatures showed up with just the proteomics, and some only showed up with all 3 profiles [transcriptome, proteome, metabolome].... There's really more information in all 3 than in any 1 of these alone," Dr. Snyder added. "We didn't know that for sure going in, but it was refreshing and somewhat reassuring to see this. It makes sense that you'll get a more complete picture when you follow everything."
One goal of the study was to compare molecular analyses in health and disease. Dr. Snyder developed 2 viral infections during the study: a rhinovirus infection on day 0, and a respiratory syncytial virus (RSV) infection starting on day 289. Twelve days later (day 301), his glucose levels became elevated. The elevation lasted several months until, based on glucose levels and HbA1c, his physician diagnosed type 2 diabetes on day 369. "People have associated diabetes with stress responses before, but to the best of my knowledge, not with viral infections. So this was a new angle," Dr. Snyder noted. "It could be that the virus acted like a stress inducer. Our interpretation of this is that my genome has me predisposed and that, in combination with the viral infection, maybe the stress-response part of the viral infection induced the disease." Asked why this infection induced diabetes when previous infections had not, Dr. Snyder said: "This RSV is a pretty nasty one. Another factor may be the case as well: I'm in my 50s and, to be honest, that's when things break down. It's quite likely that the combination of being in my 50s, with this viral stress and, again, my genome combination is what triggered it."
Diabetes should be regarded as "hundreds of diseases," noted Dr. Snyder. "Some people are insulin-resistant, some aren't; some respond to metformin, some don't; some seem to be associated with inflammation, some aren't. So I think diabetes probably is many diseases, all lumped together, because the 1 common characteristic is high glucose. I'm hopeful that by doing more of these sorts of studies, we can look at the molecular breakdown of how many types there are, and then be able to better stratify it and better treat it," Dr. Snyder said.
"I foresee that a longitudinal 'Omics' study as described in Snyder's landmark paper will indeed become common in the next 10 to 20 years," said Jan Korbel, PhD, group leader at the European Molecular Biology Laboratory, Heidelberg, Germany.
"A first promising application would be in families with particular hereditary risk factors, where whole-omics profiling could be used to monitor disease onset closely." George M. Church, PhD, professor of genetics at Harvard Medical School, Boston, Massachusetts, anticipates that work-ups of this type might become common for individuals in "maybe 4 years."
Eric J. Topol, MD, professor of translational genomics at the Scripps Research Institute, La Jolla, California, expects that such work-ups could "be common now for select individuals with a rare, disabling, even life-threatening condition.
Unlike the Snyder study of 20 serial blood draws...a single assessment is eminently doable and could shed considerable light on root cause and potential targeted therapy." "I think it's going to be the future of medicine," concluded Dr. Snyder. "I'd love to see medicine in the future be a case where you get a little prick in your finger, just like a diabetes test, and you measure 5000 things instead of 1 thing (just glucose) right now. I'd love to see it be a home test, where you can monitor your own health routinely," he said. "That's my vision for medicine in the future."
No comments:
Post a Comment